5/8/2013

The global biosimilars market is forecast to expand to $2.5 billion this year, a growth of more than 20% from 2012, according to a report from U.K.-based firm Visiongain. The market could see rapid expansion through 2023 as biosimilar drugs enter the U.S. and European markets. Biosimilar versions of monoclonal antibodies and insulins will record the fastest growth, according to the report, which point to the potential product launches in Europe and the U.S. next year.

Full Story:
Drug Store News

Related Summaries